These data clearly demonstrated that a peptide conjugate composed of [F7, P34]-NPY and tesa is as efficient as free tesa and is thus a promising drug candidate that potentially reduces the known side effects of non-selective PPARγ agonists for the treatment of T2D. This evidence concerns the gene PPARG and type 2 diabetes mellitus.